In vivo efficacy of a CD38-specific engineered toxin body.

被引：1
|
作者：
Robinson, Garrett L. [1 ]
Rajagopalan, Sangeetha [1 ]
Brieschke, Brigitte [1 ]
Erdman, Jennifer [1 ]
Neill, Jane [1 ]
Flores, Rodney [1 ]
Foree, Julia [1 ]
Null, William [1 ]
Liu, Jensing [1 ]
Higgins, Jack P. [1 ]
Willert, Erin K. [1 ]
机构：
[1] Mol Templates, Georgetown, TX USA
来源：
CLINICAL CANCER RESEARCH | 2015年 / 21卷
关键词：
D O I：
10.1158/1557-3265.HEMMAL14-A15
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A15
引用
收藏
页数：1
相关论文
共 50 条
  • [1] CD38-specific engineered toxin body: Therapeutic potential for multiple myeloma
    Rajagopalan, Sangeetha
    Brieschke, Brigitte
    Robinson, Garrett L.
    Erdman, Jennifer
    Null, William
    Higgins, Jack P.
    Willert, Erin K.
    CANCER RESEARCH, 2014, 74 (19)
  • [2] CD38-specific nanobodies allow in vivo imaging of multiple myeloma under daratumumab therapy
    Pape, Luca Julius
    Hambach, Julia
    Gebhardt, Anna Josephine
    Rissiek, Bjoern
    Staehler, Tobias
    Tode, Natalie
    Khan, Cerusch
    Weisel, Katja
    Adam, Gerhard
    Koch-Nolte, Friedrich
    Bannas, Peter
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [3] Perspectives for the Development of CD38-Specific Heavy Chain Antibodies as Therapeutics for Multiple Myeloma
    Bannas, Peter
    Koch-Nolte, Friedrich
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [4] In vivo efficacy of a PD-L1 targeted, antigen seeding engineered toxin body
    Ramos, Hilario J.
    Brieschke, Brigitte
    LeMar, Sara
    Dekker, Joseph D.
    Iberg, Aimee
    Robinson, Garrett L.
    Sarkar, Asis
    Anand, Banmeet
    Singh, Melissa M.
    Zhao, Jay
    Higgins, Jack P.
    Willert, Erin K.
    CANCER RESEARCH, 2020, 80 (16)
  • [5] Nanobody-based CD38-specific CARs and BiKEs sent into race against multiple myeloma
    Hambach, J.
    Gebhardt, A. J.
    Pape, L.
    Fumey, W.
    Schutze, K.
    Stahler, T.
    Adam, G.
    Riecken, K.
    Fehse, B.
    Weisel, K.
    Koch-Nolte, F.
    Bannas, P.
    HUMAN GENE THERAPY, 2022, 33 (23-24) : A128 - A128
  • [6] CD38-Specific CAR Integrated into CD38 Locus Driven by Different Promoters Causes Distinct Antitumor Activities of T and NK Cells
    Liao, Chan
    Wang, Yajie
    Huang, Yanjie
    Duan, Yanting
    Liang, Yan
    Chen, Jiangqing
    Jiang, Jie
    Shang, Kai
    Zhou, Chun
    Gu, Ying
    Liu, Nan
    Zeng, Xun
    Gao, Xiaofei
    Tang, Yongmin
    Sun, Jie
    ADVANCED SCIENCE, 2023, 10 (27)
  • [7] Preclinical evaluation of the CD38-targeting engineered toxin body MT-0169 against multiple myeloma
    Bruins, Wassilis S. C.
    Rentenaar, Rosa
    Newcomb, John
    Zheng, Wenrou
    Ruiter, Ruud W. J.
    Baardemans, Thomas
    Poma, Eric
    Moore, Chris
    Robinson, Garrett L.
    Lublinsky, Anya
    Zhang, Yuhong
    Syed, Sakeena
    Milhollen, Michael
    Dash, Ajeeta B.
    van de Donk, Niels W. C. J.
    Groen, Richard W. J.
    Zweegman, Sonja
    Mutis, Tuna
    HEMASPHERE, 2024, 8 (11):
  • [8] MT-4019: a de-immunized engineered toxin body targeting CD38 for multiple myeloma
    Robinson, Garrett L.
    Rajagopalan, Sangeetha
    Brieschke, Brigitte
    Neill, Jane
    Erdman, Jennifer
    Flores, Rodney
    Liu, Jensing
    Higgins, Jack P.
    Willert, Erin K.
    CANCER RESEARCH, 2017, 77
  • [9] Mouse CD38-Specific Heavy Chain Antibodies Inhibit CD38 GDPR-Cyclase Activity and Mediate Cytotoxicity Against Tumor Cells
    Baum, Natalie
    Eggers, Marie
    Koenigsdorf, Julia
    Menzel, Stephan
    Hambach, Julia
    Staehler, Tobias
    Fliegert, Ralf
    Kulow, Frederike
    Adam, Gerhard
    Haag, Friedrich
    Bannas, Peter
    Koch-Nolte, Friedrich
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [10] Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells
    Zhitao Gao
    Chuan Tong
    Yao Wang
    Deyun Chen
    Zhiqiang Wu
    Weidong Han
    JournalofGeneticsandGenomics, 2019, 46 (08) : 367 - 377
12345